Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Balancing on a tightrope, pharma’s generative AI journey straddles fear and FOMO

By Brian Buntz | July 28, 2023

[vetal1983/Adobe Stock]

Pharma and biotech companies have had a spectrum of responses to the surge in generative artificial intelligence (AI). A recent Washington Post article describes an unnamed biotech firm that banned employees from using OpenAI’s ChatGPT despite its capability to bolster productivity given concerns over potential data leaks. At the same time, the burgeoning AI landscape have created a fear of missing out, or FOMO, among businesses, including the pharma sector. “There’s this fear of missing out that I think is driving everybody to do something,” said Scott Snyder, chief digital officer at Eversana. On a tightrope of fear and FOMO, the pharmaceutical industry’s journey with generative AI continues with some companies taking more of a wait-and-see approach and others forging ahead with the technology to, for instance, discovery novel compounds.

Eversana is among those that are taking action. The company recently announced a partnership with AWS to increase adoption of generative AI in life sciences.

Pharma’s generative AI journey: Balancing fear, FOMO and practical experimentation

Scott Snyder

Scott Snyder

Looking at the landscape, Snyder said that a lot of firms are in the experimentation phase with the technology. Snyder describes the current landscape as a time of experimentation, with companies figuring out their path. “Right now, it’s a lot of experimentation for a couple of companies that have really leaned into certain use cases,” he says. For instance, some companies are using AI for regulatory document processing, while others are exploring automation of adverse event case intake.

Generative AI in particular offers potential to accelerate “content velocity,” Snyder said. Although not error-free, it can both generate and also analyze content at superhuman speeds. Generative AI’s capabilities make it possible to, say, take a piece of educational information on a disease and produce hundreds of versions of it for distinct demographics — supporting a variety of languages and locales. “Maybe that resonates with different age groups or demographics, instead of having to go back to the studio or the design board every time,” Snyder said. “That’s one thing generative AI can do really well — ‘Hey, pick this video, but make it localized for Peru right?'” he said. “And so it might not get you 100% of the way there, but it might allow the designer to say I can finish the last 10%.” Similarly, generative AI tools could cut the review time for medical documents by 50% to 80%, Snyder estimated.

But generative AI offers more than efficiency for niche use case. The technology could fundamentally transform pharma’s operating models, Snyder said. New AI capabilities could mean rethinking everything from patient support centers to sales team structures. Snyder describes workshops that identify high-potential AI use cases for pharma clients and assess how integrating those deployments could transform their operational roadmaps.

Navigating future uncertainties with a flexible approach

To future-proof applications of generative AI, Snyder espouses the idea of flexibility, recognizing the value in a diverse range of models suited for distinct use cases. With the number of generative AI model options quickly evolving, flexibility becomes a crucial consideration. It is important to have a diverse toolkit of models tailored to different uses. By taking a “bring-your-own-model” approach and remaining open to a spectrum of AI tools, Snyder believes companies can equip themselves for an uncertain future. Rather than betting on one horse, he recommends stacking your roster with AI tools that excel at specific functions.

To address the hesitancy of the risk-averse pharma sector, Eversana is first focusing on medical legal review. “We think if we can get that to a level where people trust it, all of a sudden, that takes a major friction point out,” he said. According to Snyder, ethical AI development frameworks could serve as the guiding light. “Every company if they don’t have one should have an ethical AI development framework,” he says, pointing out that these should highlight principles of transparency, reliability, trust, accountability and fairness.

The application of these principles, according to Snyder, leads to a more responsible AI. companies guided by such guidelines will have a measure of responsibility. “You’re going to set up sandboxes,” he said. Generative AI experiments in such environments won’t, say, cause harm to a customer before it is deployed in a production environment.

Uncharted territories: Navigating cost implications on pharma’s generative AI journey

The journey towards AI adoption is not without complexities, Snyder said. One challenge companies face currently is the uncertain cost of AI adoption. There are also options to consider. “Are you just going to pay by the drink? And have employees turn it on? Are you going to build your own models and host them?” he asked.

Snyder provides examples of potential use cases like automating medical regulatory review or accelerating literature searches on behalf of doctors. For each case, Snyder suggests, organizations can estimate time savings and the value of those savings, providing a foundation for understanding the investment required. Snyder underscores the importance of determining, say, “micro-economics of automating medical regulatory review with gen AI.”

Such calculations also allow for comparison of different implementation options. Snyder suggests that building a proprietary model, or using a hybrid public model fine-tuned to the organization’s needs, would come with different costs and risks. Once pharma companies have determined the value of time savings, they can then evaluate the type of investment necessary to achieve that value. The decision could be between building their own models or using a hybrid public model tailored to their needs. Both options, Snyder said, come with “different costs associated with them, and different risks”.

Prioritizing practical applications while staying abreast of advancements

Ultimately, Snyder advises companies to focus the majority of their efforts on immediate, viable applications, while keeping an eye on advances that could potentially disrupt the landscape. “My advice to enterprises like spend about two-thirds of their time on the low-hanging fruit use cases,” moving along with technology vendors who are already well-known in the field, he said. Snyder recommends that the remaining third of a company’s attention should be spent scanning for advancements in generative AI platforms, “because they may emerge for certain kinds of use cases and disrupt the economics or the performance.”


Filed Under: Data science, Industry 4.0, machine learning and AI
Tagged With: AI adoption, AI experimentation, biotech sector, cost considerations, ethical AI, generative AI, Pharma Industry
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Recursion-MIT AI screens thousands of molecules before a single FEP run completes
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
From data to drug candidates: Optimizing informatics for ML and GenAI
Intrepid Labs
Intrepid Labs raises $7 million to expand AI-driven formulation platform
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE